Consideration of KRAS Mutational Status May Enhance the Prognostic Impact of Indeterminate Extrahepatic Disease in the Lungs, as Identified by 18FDG-PET Scan, in Patients with Colorectal Liver Metastases

Annals of Surgery

Volumn 268, Issue 1, 2018, Pages e8-e9

  Margonis, Georgios A ^a   Andreatos, Nikolaos ^a   Pawlik, Timothy M ^b   Weiss, Matthew J ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b OHIO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUORODEOXYGLUCOSE F 18; K RAS PROTEIN; LACTIC ACID; KRAS PROTEIN, HUMAN; PROTEIN P21;

CANCER DIAGNOSIS; CANCER PROGNOSIS; CELL PROLIFERATION; CODON; COLORECTAL LIVER METASTASIS; GENE MUTATION; HUMAN; INDETERMINATE EXTRAHEPATIC DISEASE; LETTER; LIVER DISEASE; LIVER RESECTION; LUNG METASTASIS; POSITRON EMISSION TOMOGRAPHY; PREOPERATIVE CARE; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TREATMENT CONTRAINDICATION; COLORECTAL TUMOR; LIVER TUMOR; PROGNOSIS; RETROSPECTIVE STUDY;

COLORECTAL NEOPLASMS; FLUORODEOXYGLUCOSE F18; HUMANS; LIVER NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; PROGNOSIS; PROTO-ONCOGENE PROTEINS P21(RAS); RETROSPECTIVE STUDIES;

EID: 85046992738     PISSN: 00034932     EISSN: 15281140     Source Type: Journal    
DOI: 10.1097/SLA.0000000000002264     Document Type: Letter

References (10)

1. Wong GY, Kumar R, Beeke C,. Survival outcomes for patients with indeterminate 18FDG-PET scan for extrahepatic disease before liver resection for metastatic colorectal cancer: a retrospective cohort study using a prospectively maintained database to analyze survival outcomes for patients with indeterminate extrahepatic disease on 18FDG-PET scan before liver resection for metastatic colorectal cancer. Ann Surg 2017; doi: 10.1097/SLA.0000000000002170. [Epub ahead of print].
2. Leung U, Gonen M, Allen PJ,. Colorectal cancer liver metastases and concurrent extrahepatic disease treated with resection. Ann Surg 2017; 265: 158-165.
3. Cejas P, Lopez-Gomez M, Aguayo C,. KRAS mutations in primary colorectal cancer tumors and related metastases: a potential role in prediction of lung metastasis. PLoS One 2009; 4: e8199.
4. Margonis GA, Spolverato G, Kim Y,. Effect of KRAS mutation on long-term outcomes of patients undergoing hepatic resection for colorectal liver metastases. Ann Surg Oncol 2015; 22: 4158-4165.
5. Vauthey JN, Zimmitti G, Kopetz SE,. RAS mutation status predicts survival and patterns of recurrence in patients undergoing hepatectomy for colorectal liver metastases. Ann Surg 2013; 258: 619-626. discussion 626-617.
6. Andreatos N, Ronnekleiv-Kelly S, Margonis GA,. From bench to bedside: Clinical implications of KRAS status in patients with colorectal liver metastasis. Surg Oncol 2016; 25: 332-338.
7. Margonis GA, Kim Y, Sasaki K,. Codon 13 KRAS mutation predicts patterns of recurrence in patients undergoing hepatectomy for colorectal liver metastases. Cancer 2016; 122: 2698-2707.
8. Margonis GA, Kim Y, Spolverato G,. Association between specific mutations in KRAS codon 12 and colorectal liver metastasis. JAMA Surg 2015; 150: 722-729.
9. Hutton JE, Wang X, Zimmerman LJ,. Oncogenic KRAS and BRAF drive metabolic reprogramming in colorectal cancer. Mol Cell Proteomics 2016; 15: 2924-2938.
10. Kawada K, Toda K, Nakamoto Y,. Relationship between 18F-FDG PET/CT scans and KRAS mutations in metastatic colorectal cancer. J Nucl Med 2015; 56: 1322-1327.